Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07089901 · ClinicalTrials.gov registry record · Phase 4

Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment

A Phase 4 study, sponsored by Duke University.

Recruiting
Registry status
Phase 4
Development phase
600
Enrollment target

NCT07089901: Recruiting Phase 4 study, sponsored by Duke University.

NCT07089901 is a Phase 4 study that is actively recruiting participants, run by Duke University. The registered enrollment target is 600 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (16% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07089901, a Phase 4 study, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
Phase 4
Development phase
600 participants
Enrollment target

Study Summary

Tobacco use is a chronic relapsing condition. That is, even with state-of-the-art treatment, \>70% of smoking cessation attempts end in a return to regular smoking. Research demonstrates that everyday environments associated with smoking trigger craving for cigarettes, provoke smoking, and lead to relapse. However, despite this knowledge, understanding of environmental correlates of smoking has been limited by a reliance on self-report, leading to imprecise information about the physical environments in which people live. To overcome this challenge, the research team has pioneered the development of digital envirotyping, which uses digital tools (e.g., sensors, cameras, artificial intelligence) to efficiently and accurately characterize and categorize environments with the goal of identifying environmental markers of behavior and health. Foundational to the digital envirotyping research is computer vision (CV), a type of artificial intelligence (AI) that enables computer systems to recognize objects and scenes in digital images, mimicking how humans perceive and understand visual information. With CV researchers can extract detailed and accurate information (i.e., objects and location types) about the everyday environments of people who smoke (PWS) and relate that information to smoking behavior. After validating the use of CV, the researchers used CV to develop enviromarkers of relapse risk. Importantly, they identified a novel enviromarker in which people at greater risk for relapse when they quit are exposed to a more consistent level of environment-related smoking risk as they move between their smoking and nonsmoking environments. Research is now needed to advance digital envirotyping and enviromarker development in the field of tobacco addiction. The study will recruit a diverse, national sample of n=500 adults who are interested in quitting smoking. For two weeks prior to quitting, they will undergo photoEMA in which they will take two pictures of their curr

Primary Outcome

Participants will self-report smoking from quit date to the 6-month follow-up visit. Days to relapse will be defined as the first of seven consecutive days of smoking.

Interventions

  • DRUG transdermal nicotine replacement therapy

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2026-05-06
Est. Completion 2030-03-31
Phase Phase 4
Duke University

1,725 total trials

What NCT07089901 shows while recruiting

NCT07089901 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (16% higher).

The record links to 0 conditions, and to 1 intervention - of which transdermal nicotine replacement therapy is the first listed.

NCT07089901 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07089901 about?

NCT07089901 is a clinical study titled "Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment". Tobacco use is a chronic relapsing condition. That is, even with state-of-the-art treatment, \>70% of smoking cessation attempts end in a return to regular smoking. Research demonstrates that everyday environments associated with smoking trigger craving for cigarettes, provoke smoking, and lead to r...

What is the current status of trial NCT07089901?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 2026-05-06. Estimated completion is 2030-03-31.

What interventions are being tested in trial NCT07089901?

The interventions under investigation include: transdermal nicotine replacement therapy (DRUG).

Who is sponsoring clinical trial NCT07089901?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07089901's enrollment target sits among peer trials

600 137th of 2000 higher than 1,854 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07089901, the US trial registry maintained by the National Library of Medicine. NCT07089901 (mid enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.